Normal scar tissue forms to heal an internal wound and quietly retreats when the job is done. But in many common diseases — kidney, liver and lung fibrosis — the scar tissue goes rogue and strangles vital organs. These diseases are largely untreatable and ultimately fatal.
A new Northwestern Medicine study has newly identified a trigger of some fibrotic diseases and an experimental compound to treat it.
Fibrosis — a progressive scarring and hardening of internal organs — is estimated to cause 35 to 40 percent of deaths in the world. Fibrotic diseases include diabetic kidney fibrosis, alcoholic liver cirrhosis, hepatitis C, pulmonary fibrosis and nonalcoholic fatty liver disease, which may lead to fibrosis of the liver, the leading cause of liver transplant.
In one subset of human fibrosis cells, scientists discovered a delinquent gang of molecules that continually shouted at an immune receptor — the antennae on the cell — to produce scar tissue instead of quieting down and allowing the scar tissue to go back to sleep.
Scientists collaborated with a University of Colorado researcher who used crystallography and computer modeling to predict a molecule that could block the receptor that leads to the uncontrolled scarring. When they tested the molecule, T53, in three different mouse models of fibrosis, the abnormality was significantly reversed.
“Our study opens a new door into fibrosis by looking at it as an aberrant innate immune response and suggesting a novel approach to treat it,” said senior author Dr. John Varga, director of the Northwestern Scleroderma Program and the John and Nancy Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg School of Medicine.
The paper was published July 12 in the Journal of Clinical Investigation Insight.
“The leading cause of liver failure in western world is obesity and that’s because of liver fibrosis,” Varga said. “In the U.S., many of these diseases are lifestyle or age dependent. As we get fatter or older, they get worse.”
Most fibrotic disease likely begins as normal repair of an injury, scientists said. “But if the immune system produces too much of an initial scar, it can’t go back to normal,” Varga said. “You have an unhealed scar that keeps growing and can wipe out the entire organ.”
Not everyone’s fibrosis is caused by the same abnormality, Varga said. If the compound, T53, is eventually developed into an approved drug, it would be targeted to patients with the specific genetic signature identified in the study.
“There is an emerging direction for treating fibrosis with precision medicine,” said first author Swati Bhattacharyya, research associate professor of medicine in rheumatology and scientific director of the Scleroderma Research Laboratory at Feinberg. “Some people live with fibrotic disease for 30 years while others die in two years. We need to identify the rapid progressors from the slow progressors. That’s where precision medicine becomes really critical.”
“The results of this study are encouraging,” Varga said. “We are not saying this compound is ready to be a drug. It’s an initial compound that would need to be developed and tweaked. It would need significant funding to go to the next step.”
Learn more: Why internal scars won’t stop growing
The Latest on: Fibrosis
via Google News
The Latest on: Fibrosis
- Non-Cystic Fibrosis Bronchiectasis Pipeline Insights, 2021on April 21, 2021 at 3:56 pm
Non-Cystic Fibrosis Bronchiectasis Pipeline ” has been added to DelveInsight Non-Cystic Fibrosis Bronchiectasis Pipeline analysis across different stages of development (Phase III and Phase II), ...
- Call The Midwife star reveals cystic fibrosis crusadeon April 21, 2021 at 10:00 am
Cystic fibrosis affects my family,” says Call The MidWife star Jenny Agutter, who is a patron of the Cystic Fibrosis Trust. “I’m a carrier like one in 25 people." ...
- Nuformix eyes big opportunity with new forms of fibrosis and cancer drugson April 21, 2021 at 6:09 am
By developing new forms of safe drugs, the company generates its own intellectual property and may shorten the timeline to market ...
- Global Idiopathic Pulmonary Fibrosis Market...on April 21, 2021 at 2:26 am
The "Idiopathic Pulmonary Fibrosis - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global ...
- Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver diseaseon April 20, 2021 at 5:00 pm
Objective Emerging data suggest that a 30% relative decline in liver fat, as assessed by MRI-proton density fat fraction (MRI-PDFF), may be associated with Non-Alcoholic Fatty Liver Disease Activity ...
- Kidney (Renal) Fibrosis Market | Manufacturers, Types, Regions, Application and Forecast 2021 - 2028 By Ameco Researchon April 20, 2021 at 2:58 am
Fibrosis Market primary data collection was achieved by interviewing the retailers and the consumers. The interviews were conducted through one to one structured questionnaire supervision. The global ...
- Changing Market Dynamics of Non-Cystic Fibrosis Bronchiectasis Market in the 7 Major Marketson April 19, 2021 at 11:43 pm
Non-Cystic Fibrosis Bronchiectasis Market report has been added to DelveInsight. The Non-Cystic Fibrosis Bronchiectasis Market report provides an edge while d ...
- The adipokine orosomucoid alleviates adipose tissue fibrosis via the AMPK pathwayon April 19, 2021 at 1:16 pm
The excess deposition of underlying extracellular matrix (ECM) in adipose tissue is defined as adipose tissue fibrosis that is a major contributor to metabolic disorder such as obesity and type 2 ...
- Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cellson April 13, 2021 at 7:27 am
Systemic sclerosis (SSc) is a life-threatening chronic connective tissue disease with the characteristics of skin fibrosis, vascular injury, and inflammatory infiltrations. Though inhibition of ...
via Bing News